Practical Consensus Recommendations for Optimizing Risk versus Benefit of Chemotherapy in Patients with HR Positive Her2 Negative Early Breast Cancer in India

被引：7

作者：

Parikh, Purvish M. ^{[1
]}

Bhattacharyya, Gouri Shankar ^{[2
]}

Biswas, Ghanshyam ^{[3
]}

Krishnamurty, Arvind ^{[4
]}

Doval, Dinesh ^{[5
]}

Heroor, Anil ^{[6
]}

Sharma, Sanjay ^{[7
]}

Deshpande, Ramakant ^{[7
]}

Chaturvedi, Harit ^{[8
]}

Somashekhar, S. P. ^{[9
]}

Babu, Govind ^{[10
]}

Reddy, G. Krishna ^{[11
]}

Sarkar, Diptendra ^{[12
,13
]}

Desai, Chirag ^{[14
]}

Malhotra, Hemant ^{[15
]}

Rohagi, Nitesh ^{[16
]}

Bapna, Ajay ^{[17
]}

Alurkar, S. S. ^{[18
]}

Krishna, Prasad ^{[19
]}

Deo, S. V. S. ^{[20
]}

Shrivastava, Anurag ^{[21
]}

Chitalkar, Prakash ^{[22
]}

Majumdar, Saroj Kumar ^{[23
]}

Vijay, Devanhalli ^{[24
]}

Thoke, Aniket ^{[25
]}

Udupa, K. S. ^{[26
]}

Bajpai, Jyoti ^{[27
]}

Rath, G. K. ^{[28
]}

Dattatreya, Palanki Satya ^{[29
]}

Bondarde, Shailesh ^{[30
]}

Patil, Shekhar ^{[10
]}

机构：

[1] Mumbai Oncocare Ctr, Mumbai, Maharashtra, India

[2] Fortis Hosp, Kolkata, W Bengal, India

[3] Sparsh Hosp & Crit Care, Med Oncol, Bhubaneswar, India

[4] Canc Inst Adyar, Surg Oncol, Chennai, Tamil Nadu, India

[5] Rajiv Gandhi Canc Inst & Res Ctr, Med Oncol, Delhi, India

[6] Fortis Hosp, Surg Oncol, Mumbai, Maharashtra, India

[7] Asian Canc Inst, Surg Oncol, Mumbai, Maharashtra, India

[8] Max Inst Canc Care, Surg Oncol, Delhi, India

[9] Manipal Hosp, Manipal Comprehens Canc Ctr, Surg Oncol, Bangalore, Karnataka, India

[10] HCG Canc Hosp, Med Oncol, Bengaluru, India

[11] Manipal Hosp, Med Oncol, Vijaywada, India

[12] Inst Postgrad Med Educ & Res, Surg Oncol, Kolkata, India

[13] Seth Sukhlal Karnani Mem Hosp, Kolkata, India

[14] Vedanta Inst Med Sci, Med Oncol, Ahmadabad, Gujarat, India

[15] MG Hosp, Med Oncol, Jaipur, Rajasthan, India

[16] Max Inst Canc Care, Med Oncol, Delhi, India

[17] Bhagwan Mahaveer Canc Hosp & Res Ctr, Med Oncol, Jaipur, Rajasthan, India

[18] Apollo Hosp, Med Oncol, Ahmadabad, Gujarat, India

[19] Mangalore Inst Oncol, Med Oncol, Mangalore, India

[20] All India Inst Med Sci, Surg Oncol, Delhi, India

[21] All India Inst Med Sci, Surg, Delhi, India

[22] Sri Aurobindo Med Coll & Postgrad Inst, Med Oncol, Indore, India

[23] AIIMS, Radiat Oncol, Bhubaneswar, India

[24] HCG Canc Hosp, Surg Oncol, Ahmadabad, Gujarat, India

[25] Sanjeevani CBCC USA Canc Hosp, Radiat Oncol, Raipur, Madhya Pradesh, India

[26] Kasturba Med Coll & Hosp, Med Oncol, Manipal, India

[27] Tata Mem Hosp, Med Oncol, Mumbai, Maharashtra, India

[28] DR BRA Inst Rotary Canc Hosp, Radiat Oncol, Delhi, India

[29] Omega Hosp, Med Oncol, Hyderabad, India

[30] Shatabdi Super Special Hosp, Med Oncol, Nasik, India

来源：

SOUTH ASIAN JOURNAL OF CANCER | 2021年 / 10卷 / 04期

关键词：

avoiding financial distress; avoiding toxicity; COVID-19; low- and middle-income countries; personalized therapy; precision oncology; saving lives; ADJUVANT CHEMOTHERAPY; PREMENOPAUSAL WOMEN; COST-EFFECTIVENESS; ENDOCRINE THERAPY; CLINICAL UTILITY; YOUNG-WOMEN; SURVIVAL; OVERTREATMENT; RECURRENCE; PREDICTION;

D O I：

10.1055/s-0041-1742080

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Breast cancer is a public health challenge globally as well as in India. Improving outcome and cure requires appropriate biomarker testing to assign risk and plan treatment. Because it is documented that significant ethnic and geographical variations in biological and genetic features exist worldwide, such biomarkers need to be validated and approved by authorities in the region where these are intended to be used. The use of western guidelines, appropriate for the Caucasian population, can lead to inappropriate overtreatment or undertreatment in Asia and India. A virtual meeting of domain experts discussed the published literature, real-world practical experience, and results of opinion poll involving 185 oncologists treating breast cancer across 58 cities of India. They arrived at a practical consensus recommendation statement to guide community oncologists in the management of hormone positive (HR-positive) Her2-negative early breast cancer (EBC). India has a majority (about 50%) of breast cancer patients who are diagnosed in the premenopausal stage (less than 50 years of age). The only currently available predictive test for HR-positive Her2-negative EBC that has been validated in Indian patients is CanAssist Breast. If this test gives a score indicative of low risk (< 15.5), adjuvant chemotherapy will not increase the chance of metastasis-free survival and should not be given. This is applicable even during the ongoing COVID-19 pandemic.

引用

页码：213 / 219

页数：7

共 65 条

[1]

Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0

[2] Spectrum of breast cancer in Asian women [J].

Agarwal, Gaurav ;

Pradeep, P. V. ;

Aggarwal, Vivek ;

Yip, Cheng-Har ;

Cheung, Polly S. Y. .

WORLD JOURNAL OF SURGERY, 2007, 31 (05) :1031-1040

[3] Practical consensus recommendations on management of HR [J].

Aggarwal, S. ;

Vaid, A. ;

Ramesh, A. ;

Parikh, Purvish M. ;

Purohit, S. ;

Avasthi, B. ;

Gupta, S. ;

Ranjan, S. ;

Kaushal, V. ;

Salim, S. ;

Singh, R. ;

Minhas, S. ;

Doval, D. .

SOUTH ASIAN JOURNAL OF CANCER, 2018, 7 (02) :96-101

[4] Global surveillance of cancer survival 1995-2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2) [J].

Allemani, Claudia ;

Weir, Hannah K. ;

Carreira, Helena ;

Harewood, Rhea ;

Spika, Devon ;

Wang, Xiao-Si ;

Bannon, Finian ;

Ahn, Jane V. ;

Johnson, Christopher J. ;

Bonaventure, Audrey ;

Marcos-Gragera, Rafael ;

Stiller, Charles ;

Azevedo e Silva, Gulnar ;

Chen, Wan-Qing ;

Ogunbiyi, Olufemi J. ;

Rachet, Bernard ;

Soeberg, Matthew J. ;

You, Hui ;

Matsuda, Tomohiro ;

Bielska-Lasota, Magdalena ;

Storm, Hans ;

Tucker, Thomas C. ;

Coleman, Michel P. .

LANCET, 2015, 385 (9972) :977-1010

[5] Analytical validation of CanAssist-Breast: an immunohistochemistry based prognostic test for hormone receptor positive breast cancer patients [J].

Attuluri, Arun Kumar ;

Serkad, Chandra Prakash V. ;

Gunda, Aparna ;

Ramkumar, Charusheila ;

Basavaraj, Chetana ;

Buturovic, Ljubomir ;

Madhav, Lekshmi ;

Naidu, Nirupama ;

Krishnamurthy, Naveen ;

Prathima, R. ;

Kanaldekar, Suchita ;

Bakre, Manjiri M. .

BMC CANCER, 2019, 19 (1)

[6]

Badwe R A, 1990, Indian J Cancer, V27, P220

[7] Patient Navigation in Breast Cancer Treatment and Survivorship: A Systematic Review [J].

Baik, Sharon H. ;

Gallo, Linda C. ;

Wells, Kristen J. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (30) :3686-+

[8] Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patients [J].

Bakre, Manjiri M. ;

Ramkumar, Charusheila ;

Attuluri, Arun Kumar ;

Basavaraj, Chetana ;

Prakash, Chandra ;

Buturovic, Ljubomir ;

Madhav, Lekshmi ;

Naidu, Nirupama ;

Prathima, R. ;

Somashekhar, S. P. ;

Gupta, Sudeep ;

Doval, Dinesh Chandra ;

Pegram, Mark D. .

CANCER MEDICINE, 2019, 8 (04) :1755-1764

[9]

Bapna A., 2018, PRENSA MED ARGENT, V105, P1

[10] Oncotype DX: Where Does It Stand in India? [J].

Batra, Atul ;

Patel, Amol ;

Gupta, Vineet Govinda ;

Mehta, Prashant ;

Tvsvgk, Tilak ;

Biswas, Bivas ;

Pramanik, Raja ;

Das, Chandan Krishnan ;

Srivastava, Priyanka .

JOURNAL OF GLOBAL ONCOLOGY, 2019, 5

← 1 2 3 4 5 6 7 →